stockrowGilead Sciences, Inc. (GILD) vs Novo Nordisk A/S (NVO)
- Gilead Sciences, Inc. GILD 166.89 −0.41%
- Novo Nordisk A/S NVO 40.31 +0.02%
Gilead Sciences, Inc. and Novo Nordisk A/S are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $207.8B against $134.8B — 1.5× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Novo Nordisk A/S trades at 10.1×. Novo Nordisk A/S grew revenue faster over the last twelve months: 11.1% against 6.54%. Novo Nordisk A/S has the higher net margin (34.1% vs −12.5%) and the higher return on invested capital (29.6% vs −4.51%). Both pay a dividend; Novo Nordisk A/S yields more (4.46% vs 1.95%). Across the 22 metrics below, Novo Nordisk A/S leads on 16 and Gilead Sciences, Inc. on 6.
Valuation
Profitability
| Metric | GILD | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.93% | 80.89% | 73.01% |
| Operating margin | (7.63%) | 42.66% | 18.34% |
| Net margin | (12.47%) | 34.09% | 7.31% |
| Free cash flow margin | 44.47% | 13.25% | 18.56% |
| Return on equity | (22.45%) | 58.84% | 5.80% |
| Return on assets | (7.03%) | 20.52% | 2.28% |
| Return on invested capital | (4.51%) | 29.63% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack